micro-community-banner
Profile Image
  • Add Media
  • Saved

3w
Microbes, mood, and metabolism/obesity: Pharmacological insights into the gut-obesity-depression triad - PubMed

Microbes, mood, and metabolism/obesity: Pharmacological insights into the gut-obesity-depression triad - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41774188/

The global rise in obesity and depression, two highly prevalent and often comorbid disorders has intensified interest in the gut-brain axis as a shared biological link. Mounting evidence indicates that...

Review links gut dysbiosis to obesity-depression comorbidity via SCFAs, GLP-1, bile acids modulating metabolism, inflammation, mood through gut-brain axis; GLP-1RAs (semaglutide), psychobiotics, FMT offer dual-targeting therapeutic promise.

Profile Image
  • Saved

3w

Did you know? Experts highlight that relying solely on BMI may overlook important phenotypic differences in obesity and associated cardiometabolic risks. Recent consensus recommendations emphasize integrating anthropometric, biochemical, and emerging digital tools to better capture obesity heterogeneity and guide more personalized prevention and management strategies.

Could expanding obesity assessment beyond BMI help improve risk stratification and clinical decision-making in patients with obesity?

pharmacologic therapy

Could expanding obesity assessment beyond BMI help improve risk stratification and clinical decision-making in patients with obesity?

Profile Image
  • Saved

4w
Obesity care in Chinese adults: from evidence to clinical practice - PubMed

Obesity care in Chinese adults: from evidence to clinical practice - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41446041/

More than 500 million Chinese adults suffered from overweight or obesity in 2023. The pandemic of obesity consumes healthcare and economic resources by imposing enormous burden from its complications such...

Obesity in Chinese adults is rising, driving health burden; policies, lifestyle interventions, digital health, and novel therapies are advancing care, but challenges include disparities, misdiagnosis, and need for multidisciplinary collaboration.

Profile Image
  • Saved

1mo
Profile Image
  • Saved

1mo
Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations - PubMed

Evaluating the Safety Profile of Glucagon-Like Peptide-1 Receptor Agonists: Adverse Events and Clinical Recommendations - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41819567/

The rising global prevalence of obesity and its associated health problems necessitate effective intervention strategies. Historically, many anti-obesity medications have been developed and later withdrawn because of unfavorable adverse event...

Review evaluates safety of GLP-1 receptor agonists for obesity, highlighting significant weight-loss and cardiometabolic benefits while addressing adverse events such as retained gastric contents and aspiration, with clinical recommendations for safer use.

Profile Image